Loading clinical trials...
Loading clinical trials...
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Conditions
Interventions
Custirsen, paclitaxel and carboplatin
Locations
4
United States
Teva Investigational Site 002
Detroit, Michigan, United States
Teva Investigational Site 001
Dallas, Texas, United States
Teva Investigational Site 003
San Antonio, Texas, United States
Teva Investigational Site 004
Tacoma, Washington, United States
Start Date
April 1, 2012
Primary Completion Date
July 1, 2013
Completion Date
October 1, 2013
Last Updated
October 10, 2016
NCT06305754
NCT05198830
NCT04929028
NCT05245812
NCT04235764
NCT06316895
Lead Sponsor
Achieve Life Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions